AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|
19.7 C
New York
Wednesday, November 4, 2026

Tag: company

newsFORsourcecompanycontentinformationreleases1market

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) --

In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle-building benefits of anabolic steroids, but with a natural and safer approach.

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Unlock Your Wealth: Smart AI and Crypto Investments for Confident Women

Hey lovely money mavens! 🌟 Let's chat about two exciting opportunities in the investment world that could seriously boost your financial game. We're diving...

KIWI design Celebrates One Million Head Straps Sold, Redefines VR Comfort with Series Made for Meta Products

LOS ANGELES, June 15, 2025 /PRNewswire/ -- KIWI design, a pioneer in VR accessories, announced surpassing one million head strap sales, delivering enhanced comfort...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Current Investigation Into Compass Diversified Holdings (NYSE: CODI)

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCompany

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers